BioCentury | Nov 1, 2019
Emerging Company Profile

Tmunity: Manufacturing momentum for CAR and TCR therapies

...Gilead Sciences Inc. (NASDAQ:GILD) have NY-ESO-targeting TCR therapies in Phase II testing for solid tumors; PersonGen Biomedicine...
BioCentury | May 9, 2018
Translation in Brief

The fate of NK cells

...cell line, cord blood or peripheral blood mononuclear cells (PBMCs) without selection for education level. PersonGen Biomedicine...
BioCentury | Mar 15, 2018
Product R&D

Engineered to kill

...cells (aNK cells) Allogeneic activated NK cells Phase II Merkel cell carcinoma CARs; antibody receptors PersonGen Biomedicine...
...Hospital Frankfurt started a Phase I trial of a HER2-targeted CAR-NK cell in glioblastoma patients. PersonGen Biomedicine...
...Diego, Calif. Nkarta Inc., South San Francisco, Calif. OncoMed Pharmaceuticals Inc. (NASDAQ:OMED), Redwood City, Calif. PersonGen Biomedicine...
Items per page:
1 - 3 of 3
BioCentury | Nov 1, 2019
Emerging Company Profile

Tmunity: Manufacturing momentum for CAR and TCR therapies

...Gilead Sciences Inc. (NASDAQ:GILD) have NY-ESO-targeting TCR therapies in Phase II testing for solid tumors; PersonGen Biomedicine...
BioCentury | May 9, 2018
Translation in Brief

The fate of NK cells

...cell line, cord blood or peripheral blood mononuclear cells (PBMCs) without selection for education level. PersonGen Biomedicine...
BioCentury | Mar 15, 2018
Product R&D

Engineered to kill

...cells (aNK cells) Allogeneic activated NK cells Phase II Merkel cell carcinoma CARs; antibody receptors PersonGen Biomedicine...
...Hospital Frankfurt started a Phase I trial of a HER2-targeted CAR-NK cell in glioblastoma patients. PersonGen Biomedicine...
...Diego, Calif. Nkarta Inc., South San Francisco, Calif. OncoMed Pharmaceuticals Inc. (NASDAQ:OMED), Redwood City, Calif. PersonGen Biomedicine...
Items per page:
1 - 3 of 3